Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (388)
- Scheduling (national classification system) (171)
- Safety monitoring and information (27)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
14 result(s) found, displaying 1 to 14
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 6 March 2025
-
Corporate reportsThe Australian Sunscreen Exposure Model performs sunscreen exposure calculations that reflect the unique conditions and practices in Australia.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 November 2024
-
Corporate reportsThis plan outlines our compliance and education priorities for 2024-2025.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 March 2024
-
Corporate reportsWe commissioned the Health Design Lab to conduct market research to better understand the individual consumer, pharmacist and prescriber experiences of shortages and discontinuations.
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2022-23
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 3 March 2023
-
Corporate reportsThe TGA Pharmacovigilance Inspection Program (PVIP) metrics report for 2021 is now available.
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2021-22
-
Corporate reportsThe PVIP aims to strengthen and broaden the TGA's post-market monitoring activities and protect public health
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2019-20
-
Corporate reportsIn 2019, the TGA conducted 10 pharmacovigilance inspections of Australian medicine sponsors
-
TGA laboratory testing reportsThis testing project was designed to assess compliance with the new Standard